

Ziad A Massy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/369187/publications.pdf>

Version: 2024-02-01

271
papers

16,525
citations

25034

57
h-index

18130

120
g-index

275
all docs

275
docs citations

275
times ranked

17195
citing authors

#	ARTICLE	IF	CITATIONS
1	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , The, 2011, 377, 2181-2192.	13.7	2,087
2	Review on uremic toxins: Classification, concentration, and interindividual variability. <i>Kidney International</i> , 2003, 63, 1934-1943.	5.2	1,379
3	Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1551-1558.	4.5	740
4	Chronic kidney disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17088.	30.5	558
5	Cognitive Disorders and Dementia in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 353-363.	6.1	438
6	Vascular calcification in chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2004, 43, 572-579.	1.9	381
7	Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. <i>Kidney International</i> , 2020, 98, 1540-1548.	5.2	380
8	Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1183-1191.	0.7	371
9	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <i>Lancet</i> , The, 2014, 383, 1831-1843.	13.7	341
10	COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1973-1983.	0.7	312
11	Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. <i>American Journal of Kidney Diseases</i> , 2016, 67, 483-498.	1.9	271
12	The systemic nature of CKD. <i>Nature Reviews Nephrology</i> , 2017, 13, 344-358.	9.6	265
13	The Circulating Inactive Form of Matrix Gla Protein Is a Surrogate Marker for Vascular Calcification in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 568-575.	4.5	251
14	Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 335-340.	0.7	207
15	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 337-348.	0.7	206
16	Uremic Toxicity of Advanced Glycation End Products in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 354-370.	6.1	175
17	Atherosclerosis in CKD: differences from the general population. <i>Nature Reviews Nephrology</i> , 2010, 6, 723-735.	9.6	174
18	The European Renal Association "European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 108-122.	2.9	169

#	ARTICLE	IF	CITATIONS
19	The role of phosphate in kidney disease. <i>Nature Reviews Nephrology</i> , 2017, 13, 27-38.	9.6	166
20	Reducing major risk factors for chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 71-87.	14.2	155
21	Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 869-878.	0.7	154
22	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 727-749.	9.6	153
23	miR-223: An inflammatory oncomiR enters the cardiovascular field. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1001-1009.	3.8	147
24	The double challenge of resistant hypertension and chronic kidney disease. <i>Lancet, The</i> , 2015, 386, 1588-1598.	13.7	147
25	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012, 8, 362-369.	9.6	143
26	Changing bone patterns with progression of chronic kidney disease. <i>Kidney International</i> , 2016, 89, 289-302.	5.2	143
27	Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E-deficient Mice. <i>Circulation</i> , 2005, 112, 2875-2882.	1.6	139
28	Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. <i>Lancet Diabetes and Endocrinology,the</i> , 2014, 2, 427-436.	11.4	125
29	The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2005-2011.	4.5	124
30	Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2374-2383.	4.5	119
31	Lipid-lowering therapy in patients with renal disease. <i>Kidney International</i> , 1995, 48, 188-198.	5.2	118
32	Inorganic Phosphate Accelerates the Migration of Vascular Smooth Muscle Cells: Evidence for the Involvement of miR-223. <i>PLoS ONE</i> , 2012, 7, e47807.	2.5	105
33	High extracellular inorganic phosphate concentration inhibits RANKL signaling in osteoclast-like cells. <i>Journal of Cellular Physiology</i> , 2008, 215, 47-54.	4.1	103
34	Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1815-1820.	0.7	103
35	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2021, 99, 1280-1295.	5.2	103
36	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. <i>Lancet Diabetes and Endocrinology,the</i> , 2018, 6, 319-331.	11.4	102

#	ARTICLE	IF	CITATIONS
37	The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE ^{-/-}) mice. <i>Atherosclerosis</i> , 2009, 205, 55-62.	0.8	101
38	The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1500-1507.	0.7	81
39	Estimated Glomerular Filtration Rate Is a Poor Predictor of Concentration for a Broad Range of Uremic Toxins. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1266-1273.	4.5	79
40	Indoxyl sulphate inhibits osteoclast differentiation and function. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2176-2181.	0.7	79
41	Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. <i>Cardiovascular Research</i> , 2012, 96, 130-139.	3.8	79
42	Clinical management of the uraemic syndrome in chronic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 360-373.	11.4	78
43	Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, i52-i61.	2.9	77
44	Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity. <i>Circulation Research</i> , 2017, 121, 19-30.	4.5	76
45	MicroRNA deregulation in symptomatic carotid plaque. <i>Journal of Vascular Surgery</i> , 2015, 62, 1245-1250.e1.	1.1	75
46	The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function. <i>Toxins</i> , 2018, 10, 218.	3.4	74
47	New Insights Into the FGF23-Klotho Axis. <i>Seminars in Nephrology</i> , 2014, 34, 586-597.	1.6	73
48	Uremic toxicity and sclerostin in chronic kidney disease patients. <i>Nephrologie Et Therapeutique</i> , 2014, 10, 463-470.	0.5	71
49	Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 457-469.	2.9	70
50	Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 613-624.	2.9	68
51	Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action. <i>Cardiovascular Research</i> , 2014, 101, 256-265.	3.8	67
52	Possible involvement of microRNAs in vascular damage in experimental chronic kidney disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 88-98.	3.8	66
53	Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. <i>Cardiovascular Diabetology</i> , 2014, 13, 85.	6.8	65
54	The European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2014: a summary. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 154-169.	2.9	64

#	ARTICLE	IF	CITATIONS
55	Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2811-2823.	2.4	64
56	Magnesium and cardiovascular complications of chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2015, 11, 432-442.	9.6	62
57	Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. <i>Scientific Reports</i> , 2019, 9, 4477.	3.3	62
58	The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders. <i>Toxins</i> , 2018, 10, 303.	3.4	61
59	Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1982-1988.	0.7	60
60	Does P-Cresylglucuronide Have the Same Impact on Mortality as Other Protein-Bound Uremic Toxins?. <i>PLoS ONE</i> , 2013, 8, e67168.	2.5	60
61	Para-cresyl sulfate acutely impairs vascular reactivity and induces vascular remodeling. <i>Journal of Cellular Physiology</i> , 2015, 230, 2927-2935.	4.1	57
62	Perceived Health and Quality of Life in Patients With CKD, Including Those With Kidney Failure: Findings From National Surveys in France. <i>American Journal of Kidney Diseases</i> , 2020, 75, 868-878.	1.9	56
63	miR-126 Is Involved in Vascular Remodeling under Laminar Shear Stress. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	55
64	Neurological complications in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1606-1614.	0.7	54
65	The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1253-1262.	0.7	54
66	Vascular Toxicity of Phosphate in Chronic Kidney Disease. <i>Circulation Journal</i> , 2014, 78, 2339-2346.	1.6	53
67	Pro: Cardiovascular calcifications are clinically relevant. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 345-351.	0.7	53
68	Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 233-250.	1.6	53
69	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1211-1219.	0.7	52
70	Magnesium Attenuates Phosphate-Induced Deregulation of a MicroRNA Signature and Prevents Modulation of Smad1 and Osterix during the Course of Vascular Calcification. <i>BioMed Research International</i> , 2016, 2016, 1-11.	1.9	51
71	Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 505-513.	0.7	50
72	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1275-1284.	0.7	50

#	ARTICLE	IF	CITATIONS
73	Guanidino Compounds as Cause of Cardiovascular Damage in Chronic Kidney Disease: An in vitro Evaluation. <i>Blood Purification</i> , 2010, 30, 277-287.	1.8	49
74	LDL cholesterol in CKD – to treat or not to treat?. <i>Kidney International</i> , 2013, 84, 451-456.	5.2	49
75	Risk profile, quality of life and care of patients with moderate and advanced CKD: The French CKD-REIN Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 277-286.	0.7	49
76	microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 337-345.	3.8	48
77	The CKD Outcomes and Practice Patterns Study (CKDopps): Rationale and Methods. <i>American Journal of Kidney Diseases</i> , 2016, 68, 402-413.	1.9	47
78	Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw042.	0.7	47
79	Adverse Drug Reactions in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1090-1102.	4.5	47
80	High inorganic phosphate concentration inhibits osteoclastogenesis by modulating miR-223. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 2202-2212.	3.8	46
81	Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120. <i>Atherosclerosis</i> , 2015, 243, 248-256.	0.8	46
82	Differential Effects of Indoxyl Sulfate and Inorganic Phosphate in a Murine Cerebral Endothelial Cell Line (bEnd.3). <i>Toxins</i> , 2014, 6, 1742-1760.	3.4	45
83	A randomized multicenter trial on a lung ultrasound – guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. <i>Kidney International</i> , 2021, 100, 1325-1333.	5.2	45
84	New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 543-548.	0.7	43
85	Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2014, 36, 289-96.	0.9	42
86	The Role of Klotho on Vascular Calcification and Endothelial Function in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2014, 34, 578-585.	1.6	42
87	N-methyl-2-pyridone-5-carboxamide (2PY) – Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin. <i>Toxins</i> , 2016, 8, 339.	3.4	42
88	The mir-221/222 Cluster is a Key Player in Vascular Biology via the Fine-Tuning of Endothelial Cell Physiology. <i>Current Vascular Pharmacology</i> , 2016, 15, 40-46.	1.7	41
89	Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1597-1597.	0.7	41
90	Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2017, 16, 24.	6.8	41

#	ARTICLE	IF	CITATIONS
91	Free DNA precipitates calcium phosphate apatite crystals in the arterial wall in vivo. <i>Atherosclerosis</i> , 2017, 259, 60-67.	0.8	40
92	Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. <i>Journal of Nephrology</i> , 2017, 30, 629-634.	2.0	38
93	Mild cognitive impairment and kidney disease: clinical aspects. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 10-17.	0.7	38
94	New Insights into the Roles of Monocytes/Macrophages in Cardiovascular Calcification Associated with Chronic Kidney Disease. <i>Toxins</i> , 2019, 11, 529.	3.4	37
95	Sex Differences in Kidney Replacement Therapy Initiation and Maintenance. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1616-1625.	4.5	37
96	Uremic Toxins and Vascular Dysfunction. <i>Toxins</i> , 2020, 12, 404.	3.4	37
97	Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2020-2030.	6.1	37
98	Obesity and access to kidney transplantation in patients starting dialysis: A prospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0176616.	2.5	36
99	Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. <i>Journal of Cellular Physiology</i> , 2009, 221, 572-578.	4.1	35
100	The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0131707.	2.5	35
101	Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. <i>Journal of Clinical Hypertension</i> , 2019, 21, 991-1001.	2.0	35
102	Upregulation of BAD, a pro-apoptotic protein of the BCL2 family, in vascular smooth muscle cells exposed to uremic conditions. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 479-483.	2.1	34
103	Indirect effects of severe acute respiratory syndrome coronavirus 2 on the kidney in coronavirus disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 347-353.	2.9	34
104	Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. <i>Kidney International</i> , 2020, 97, 589-601.	5.2	32
105	Acute Kidney Injury after Open Repair of Intact Abdominal Aortic Aneurysms. <i>Annals of Vascular Surgery</i> , 2017, 39, 294-300.	0.9	31
106	International differences in chronic kidney disease prevalence: a key public health and epidemiologic research issue. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, ii129-ii135.	0.7	31
107	Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe. <i>Kidney International</i> , 2021, 100, 182-195.	5.2	31
108	The expanding roles of microRNAs in kidney pathophysiology. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 7-15.	0.7	30

#	ARTICLE	IF	CITATIONS
109	Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients. <i>Drugs in R and D</i> , 2013, 13, 165-173.	2.2	29
110	Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions. <i>Toxins</i> , 2018, 10, 404.	3.4	29
111	A multi-omics analysis of the regulatory changes induced by miR-223 in a monocyte/macrophage cell line. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 2664-2678.	3.8	29
112	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 269-280.	2.9	29
113	Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes. <i>Circulation Journal</i> , 2016, 80, 722-730.	1.6	28
114	Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe—data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1794-1804.	0.7	28
115	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. <i>Clinical Research in Cardiology</i> , 2018, 107, 214-221.	3.3	28
116	Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a potential modulator of sodium phosphate co-transporter PIT-1 expression. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2018-2030.	0.7	28
117	Effect of Simvastatin in Apolipoprotein E Deficient Mice With Surgically Induced Chronic Renal Failure. <i>Journal of Urology</i> , 2008, 179, 1631-1636.	0.4	27
118	Vascular calcification in chronic kidney disease: a review. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2013, 35, 147-161.	0.9	27
119	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1112-1114.	0.7	27
120	Data from the ERA-EDTA Registry were examined for trends in excess mortality in European adults on kidney replacement therapy. <i>Kidney International</i> , 2020, 98, 999-1008.	5.2	27
121	Distinct Effects of Inorganic Phosphate on Cell Cycle and Apoptosis in Human Vascular Smooth Muscle Cells. <i>Journal of Cellular Physiology</i> , 2015, 230, 347-355.	4.1	26
122	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii33-ii44.	0.7	26
123	Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury. <i>International Urology and Nephrology</i> , 2019, 51, 293-302.	1.4	25
124	Uremic Toxin Indoxyl Sulfate Inhibits Human Vascular Smooth Muscle Cell Proliferation. <i>Therapeutic Apheresis and Dialysis</i> , 2011, 15, 135-139.	0.9	24
125	Geographical Variations in Blood Pressure Level and Seasonality in Hemodialysis Patients. <i>Hypertension</i> , 2018, 71, 289-296.	2.7	24
126	Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation. <i>Toxins</i> , 2018, 10, 229.	3.4	24

#	ARTICLE	IF	CITATIONS
127	Vascular access conversion and patient outcome after hemodialysis initiation with a nonfunctional arteriovenous access: a prospective registry-based study. <i>BMC Nephrology</i> , 2017, 18, 74.	1.8	23
128	The association between longer haemodialysis treatment times and hospitalization and mortality after the two-day break in individuals receiving three times a week haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1577-1584.	0.7	23
129	Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 827-836.	0.7	23
130	Quantification of free and protein bound uremic toxins in human serum by LC-MS/MS: Comparison of rapid equilibrium dialysis and ultrafiltration. <i>Clinica Chimica Acta</i> , 2020, 507, 228-235.	1.1	23
131	A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. <i>Scientific Reports</i> , 2021, 11, 1784.	3.3	23
132	Empathy and stress in nurses working in haemodialysis: a qualitative study. <i>Journal of Advanced Nursing</i> , 2016, 72, 1075-1085.	3.3	22
133	Magnesium as a Calcification Inhibitor. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 281-290.	1.4	22
134	Reconsidering the Lack of Urea Toxicity in Dialysis Patients. <i>Seminars in Dialysis</i> , 2016, 29, 333-337.	1.3	21
135	ERA-EDTA invests in transformation to greener health care. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 901-903.	0.7	21
136	A Predictive Model for Progression of CKD to Kidney Failure Based on Routine Laboratory Tests. <i>American Journal of Kidney Diseases</i> , 2022, 79, 217-230.e1.	1.9	21
137	microRNAs are dysregulated in the cerebral microvasculature of CKD mice. <i>Frontiers in Bioscience - Elite</i> , 2014, E6, 80-88.	1.8	20
138	Calcium-Sensing Receptor Activation in Chronic Kidney Disease: Effects Beyond Parathyroid Hormone Control. <i>Seminars in Nephrology</i> , 2014, 34, 648-659.	1.6	20
139	Clinical Studies and Chronic Kidney Disease: What Did we Learn Recently?. <i>Seminars in Nephrology</i> , 2014, 34, 164-179.	1.6	20
140	Non-medical barriers reported by nephrologists when providing renal replacement therapy or comprehensive conservative management to end-stage kidney disease patients: a systematic review. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 848-862.	0.7	20
141	Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?. <i>Toxins</i> , 2022, 14, 280.	3.4	20
142	Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 107-113.	14.2	19
143	Access to kidney transplantation in European adults aged 75-84 years and related outcomes: an analysis of the European Renal Association-European Dialysis and Transplant Association Registry. <i>Transplant International</i> , 2018, 31, 540-553.	1.6	19
144	Endothelial Microparticles in Uremia: Biomarkers and Potential Therapeutic Targets. <i>Toxins</i> , 2019, 11, 267.	3.4	19

#	ARTICLE	IF	CITATIONS
145	Magnesium-based interventions for normal kidney function and chronic kidney disease. <i>Magnesium Research</i> , 2016, 29, 126-140.	0.5	18
146	Exploring antibody-dependent adaptive immunity against aortic extracellular matrix components in experimental aortic aneurysms. <i>Journal of Vascular Surgery</i> , 2018, 68, 60S-71S.e3.	1.1	18
147	Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry. <i>American Journal of Kidney Diseases</i> , 2019, 73, 184-193.	1.9	18
148	Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1236-1243.	2.9	18
149	Patient-reported factors influencing the choice of their kidney replacement treatment modality. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 477-488.	0.7	18
150	Drug-coated balloon angioplasty for dialysis access fistula stenosis. <i>Seminars in Vascular Surgery</i> , 2016, 29, 178-185.	2.8	17
151	Kidney transplant outcomes from older deceased donors: a paired kidney analysis by the European Renal Association-European Dialysis and Transplant Association Registry. <i>Transplant International</i> , 2018, 31, 708-719.	1.6	17
152	Difference in Profiles of the Gut-Derived Tryptophan Metabolite Indole Acetic Acid between Transplanted and Non-Transplanted Patients with Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2031.	4.1	17
153	Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2967-2976.	2.4	17
154	Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice. <i>Atherosclerosis</i> , 2013, 229, 42-51.	0.8	16
155	The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 63-70.	2.9	16
156	Protein-bound toxins: has the Cinderella of uraemic toxins turned into a princess?. <i>Clinical Science</i> , 2016, 130, 2209-2216.	4.3	15
157	The effect of differing kidney disease treatment modalities and organ donation and transplantation practices on health expenditure and patient outcomes. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 560-562.	0.7	15
158	Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 488-495.	0.7	15
159	Peritoneal Delivery of Sodium Pyrophosphate Blocks the Progression of Pre-existing Vascular Calcification in Uremic Apolipoprotein-E Knockout Mice. <i>Calcified Tissue International</i> , 2015, 97, 179-192.	3.1	14
160	Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. <i>CKJ: Clinical Kidney Journal</i> , 2016, 10, sfw060.	2.9	14
161	The measured glomerular filtration rate (mGFR) before and 6 months after bariatric surgery: A pilot study. <i>Nephrologie Et Therapeutique</i> , 2017, 13, 160-167.	0.5	14
162	Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 578-578.	2.9	14

#	ARTICLE	IF	CITATIONS
163	Magnesium supplementation: A consideration in dialysis patients. <i>Seminars in Dialysis</i> , 2018, 31, 11-14.	1.3	14
164	Vitamin K role in mineral and bone disorder of chronic kidney disease. <i>Clinica Chimica Acta</i> , 2020, 502, 66-72.	1.1	14
165	Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw409.	0.7	13
166	Predictors of nonfunctional arteriovenous access at hemodialysis initiation and timing of access creation: A registry-based study. <i>PLoS ONE</i> , 2017, 12, e0181254.	2.5	12
167	Circulating Receptor Activator of Nuclear Factor κ B Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 140.	6.8	12
168	Intestinal metabolites, chronic kidney disease and renal transplantation: Enigma Variations?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1547-1551.	0.7	11
169	Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?. <i>Drugs</i> , 2019, 79, 855-862.	10.9	11
170	Guideline attainment and morbidity/mortality rates in a large cohort of European haemodialysis patients (EURODOPPS). <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2105-2110.	0.7	11
171	International comparison of trends in patients commencing renal replacement therapy by primary renal disease. <i>Nephrology</i> , 2019, 24, 1064-1076.	1.6	11
172	Temporal trends in the quality of deceased donor kidneys and kidney transplant outcomes in Europe: an analysis by the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 175-186.	0.7	11
173	Why and how should we promote home dialysis for patients with end-stage kidney disease during and after the coronavirus 2019 disease pandemic? A French perspective. <i>Journal of Nephrology</i> , 2021, 34, 985-989.	2.0	11
174	Syndecan-1 and Free Indoxyl Sulfate Levels Are Associated with miR-126 in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10549.	4.1	11
175	From old uraemic toxins to new uraemic toxins: place of omics. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, iii2-iii5.	0.7	10
176	International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps. <i>Bone</i> , 2019, 129, 115058.	2.9	10
177	Nephrology: achieving sustainability. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2030-2033.	0.7	10
178	Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins. <i>Toxins</i> , 2021, 13, 91.	3.4	10
179	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 23-35.	2.9	10
180	The fate of triaged and rejected manuscripts. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1947-1950.	0.7	9

#	ARTICLE	IF	CITATIONS
181	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. <i>Free Radical Research</i> , 2017, 51, 14-23.	3.3	9
182	Urinary Sodium-to-Potassium Ratio and Blood Pressure in CKD. <i>Kidney International Reports</i> , 2020, 5, 1240-1250.	0.8	9
183	Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes. <i>PLoS ONE</i> , 2020, 15, e0229145.	2.5	9
184	Inhibition of miR-223 Expression Using a Sponge Strategy Decreases Restenosis in Rat Injured Carotids. <i>Current Vascular Pharmacology</i> , 2020, 18, 507-516.	1.7	9
185	Urea levels and cardiovascular disease in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 184-192.	0.7	9
186	Comment on Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies. <i>Toxins</i> 2016, 8, 358. <i>Toxins</i> , 2017, 9, 142.	3.4	8
187	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1469-1480.	0.7	8
188	Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 32.	2.7	8
189	Metformin prevents stroke damage in non-diabetic female mice with chronic kidney disease. <i>Scientific Reports</i> , 2021, 11, 7464.	3.3	8
190	Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 614-626.	3.3	8
191	The role of lipids and uremic toxins in cardiovascular disease in CKD. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 255-256.	1.6	7
192	Factors associating with differences in the incidence of renal replacement therapy among elderly: data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1428-1435.	0.7	7
193	Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1061-1072.	4.5	7
194	Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification. <i>Kidney International</i> , 2021, 99, 1382-1391.	5.2	7
195	Uremic endothelial-derived extracellular vesicles: Mechanisms of formation and their role in cell adhesion, cell migration, inflammation, and oxidative stress. <i>Toxicology Letters</i> , 2021, 347, 12-22.	0.8	7
196	New insights into acute-on-chronic kidney disease in nephrology patients: the CKD-REIN study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1700-1709.	0.7	7
197	Work status and work ability of patients receiving kidney replacement therapy: results from a European survey. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2022-2033.	0.7	7
198	Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 546-554.	4.5	7

#	ARTICLE	IF	CITATIONS
199	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 357-357.	0.7	6
200	Chronic kidney failure mineral bone disorder leads to a permanent loss of hematopoietic stem cells through dysfunction of the stem cell niche. Scientific Reports, 2018, 8, 15385.	3.3	6
201	Funding kidney research as a public health priority: challenges and opportunities. Nephrology Dialysis Transplantation, 2020, , .	0.7	6
202	Less arterial stiffness in kidney transplant recipients than chronic kidney disease patients matched for renal function. CKJ: Clinical Kidney Journal, 2021, 14, 1244-1254.	2.9	6
203	Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality. Kidney International Reports, 2021, 6, 214-218.	0.8	6
204	Severe acute respiratory syndrome coronavirus 2 indirectly damages kidney structures. CKJ: Clinical Kidney Journal, 2020, 13, 1101-1104.	2.9	6
205	SO037ANEMIA PREVALENCE AND TREATMENT AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 3-5: DATA FROM THE CHRONIC KIDNEY DISEASE OUTCOMES AND PRACTICE PATTERNS STUDY (CKDOPPS). Nephrology Dialysis Transplantation, 2016, 31, i16-i17.	0.7	5
206	Hyponatremia and MAPâ€kinase inhibitors in malignant melanoma: Frequency, pathophysiological aspects and clinical consequences. Pigment Cell and Melanoma Research, 2019, 32, 326-331.	3.3	5
207	The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?. Nephrology Dialysis Transplantation, 2020, 35, 1073-1075.	0.7	5
208	Gut microbiota orchestrates PTH action in bone: role of butyrate and T cells. Kidney International, 2020, 98, 269-272.	5.2	5
209	Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study. CKJ: Clinical Kidney Journal, 2021, 14, 1798-1807.	2.9	5
210	Role of proteinuria in the anemia of chronic kidney disease. Kidney International, 2021, 100, 1160-1162.	5.2	5
211	Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome. Archives of Cardiovascular Diseases, 2022, 115, 87-95.	1.6	5
212	The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 798-807.	2.9	5
213	Activin receptor IIA ligand trapâ€in chronic kidney disease: 1 drug to prevent 2 complicationsâ€or even more?. Kidney International, 2016, 89, 1180-1182.	5.2	4
214	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. Nephrology Dialysis Transplantation, 2018, 33, 1077-1082.	0.7	4
215	<i>Lancet</i> Countdown paper: what does it mean for nephrology?. Nephrology Dialysis Transplantation, 2019, 34, 4-6.	0.7	4
216	Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients aged 20â€50â€years: a study by the ERAâ€EDTA Registry. Nephrology Dialysis Transplantation, 2020, 35, 534-543.	0.7	4

#	ARTICLE	IF	CITATIONS
217	Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study. <i>Journal of Nephrology</i> , 2020, 33, 583-590.	2.0	4
218	Dietâ€™microbiota interaction and kidney disease progression. <i>Kidney International</i> , 2021, 99, 797-800.	5.2	4
219	Effect of comorbidities on survival in patients >80â€™years of age at onset of renal replacement therapy: data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 688-694.	0.7	4
220	Urgent-start dialysis in patients referred early to a nephrologistâ€™the CKD-REIN prospective cohort study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1500-1510.	0.7	4
221	Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting?. <i>Journal of Nephrology</i> , 2017, 30, 621-622.	2.0	3
222	Performance of an easy-to-use prediction model for renal patient survival: an external validation study using data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1786-1793.	0.7	3
223	Differential Determinants of Tubular Phosphate Reabsorption: Insights on Renal Excretion of Phosphates in Kidney Disease. <i>American Journal of Nephrology</i> , 2018, 47, 300-303.	3.1	3
224	Practice patterns of dialysis access and outcomes in patients wait-listed early for kidney transplantation. <i>BMC Nephrology</i> , 2020, 21, 422.	1.8	3
225	Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease. <i>Drugs in R and D</i> , 2021, 21, 231-238.	2.2	3
226	Is a treat-to-target approach to lipid-lowering therapy appropriate in patients with chronic kidney disease? A prospective French cohort study. <i>Journal of Nephrology</i> , 2021, 34, 1467-1477.	2.0	3
227	Consequences of oral antithrombotic use in patients with chronic kidney disease. <i>Clinical and Translational Science</i> , 2021, 14, 2242-2253.	3.1	3
228	Running interference: lumasiran and other RNA interference therapeutics for kidney diseases. <i>Kidney International</i> , 2022, 101, 208-211.	5.2	3
229	Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry. <i>American Journal of Kidney Diseases</i> , 2022, 79, 635-645.	1.9	3
230	Sortilin, carbamylation, and cardiovascular calcification in chronic kidney disease. <i>Kidney International</i> , 2022, 101, 456-459.	5.2	3
231	High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1731-1739.	1.8	3
232	The nephrology crystal ball: the medium-term future. <i>Nephrology Dialysis Transplantation</i> , 2019, 35, 222-226.	0.7	2
233	Vascular calcification - any place left for nicotinamide?. <i>Nephrology Dialysis Transplantation</i> , 2019, 35, 18-22.	0.7	2
234	Reply to â€™Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!â€™by Stamp et al.. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1380-1381.	2.4	2

#	ARTICLE	IF	CITATIONS
235	The association of living donor source with patient and graft survival among kidney transplant recipients in the ERA-EDTA Registry – a retrospective study. <i>Transplant International</i> , 2021, 34, 76-86.	1.6	2
236	The evolving science of anemia management in chronic kidney disease. <i>Kidney International Supplements</i> , 2021, 11, 1-2.	14.2	2
237	Phosphate meeting cholesterol’s consequences for cardiovascular disease in chronic kidney disease?. <i>Kidney International</i> , 2021, 99, 1264-1267.	5.2	2
238	Prescription of Direct Oral Anticoagulants to Patients With Moderate-to-Advanced CKD: Too Little or Just Right?. <i>Kidney International Reports</i> , 2021, 6, 2496-2500.	0.8	2
239	Can empathy be taught? A cross-sectional survey assessing training to deliver the diagnosis of end stage renal disease. <i>PLoS ONE</i> , 2021, 16, e0249956.	2.5	2
240	Role of uremic toxins in vascular disease—the end of nihilism?. <i>Kidney International</i> , 2022, 101, 1100-1102.	5.2	2
241	The Role of Uremic Retention Solutes in the MIA Syndrome in Hemodialysis Subjects. <i>Blood Purification</i> , 2023, 52, 41-53.	1.8	2
242	Chronic renal failure does not affect the mouse locomotor activity in darkness conditions. <i>Biological Rhythm Research</i> , 2013, 44, 771-777.	0.9	1
243	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 437-442.	2.9	1
244	Changes in clinical indicators related to the transition from dialysis to kidney transplantation—data from the ERA-EDTA Registry. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 188-198.	2.9	1
245	Association between Uremic Toxin Concentrations and Bone Mineral Density after Kidney Transplantation. <i>Toxins</i> , 2020, 12, 715.	3.4	1
246	A new player in the kidney’s bone axis: regulation of fibroblast growth factor-23 by renal glycerol-3-phosphate. <i>Kidney International</i> , 2020, 98, 1074-1076.	5.2	1
247	Effectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease. <i>Journal of the American Medical Directors Association</i> , 2021, , .	2.5	1
248	Low turnover bone disease in early CKD stages. <i>Kidney International Reports</i> , 2022, , .	0.8	1
249	The Author Replies:. <i>Kidney International</i> , 2014, 85, 712.	5.2	0
250	MP284CHRONIC RENAL FAILURE WORSENS ISCHEMIC STROKE SEVERITY AND NEUROLOGICAL CONSEQUENCES IN MICE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i433-i433.	0.7	0
251	MO054MORTALITY AND MAJOR CARDIOVASCULAR EVENTS ASSOCIATED WITH BLOOD PRESSURE CONTROL AND CHRONIC KIDNEY DISEASE IN THE ELDERLY. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i53-i53.	0.7	0
252	MP002TUMOR NECROSIS FACTOR-LIKE WEAK INDUCER OF APOPTOSIS FAVORS PHOSPHATE-INDUCED CALCIFICATION OF VASCULAR SMOOTH MUSCLE CELLS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i344-i344.	0.7	0

#	ARTICLE	IF	CITATIONS
253	SP375 UREMIC TOXINS ALTER ENDOTHELIAL CELL-TO-CELL JUNCTIONS'S™ STRUCTURE. Nephrology Dialysis Transplantation, 2018, 33, i472-i473.	0.7	0
254	FP511 TRENDS IN MORTALITY DUE TO MYOCARDIAL INFARCTION AND STROKE IN DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i210-i210.	0.7	0
255	FP672 BEYOND COMORBIDITY RELATED BARRIERS: FACTORS TO LIMIT THE ACCESS TO RRT MODALITIES AND CONSERVATIVE CARE. Nephrology Dialysis Transplantation, 2018, 33, i272-i272.	0.7	0
256	Renal function markers and insulin sensitivity after 3 years in a healthy cohort, the EGIR-RISC study. BMC Nephrology, 2018, 19, 124.	1.8	0
257	Acute kidney injury associated with lymphangitic carcinomatosis. CKJ: Clinical Kidney Journal, 2019, 12, 527-529.	2.9	0
258	MO072 LONGITUDINAL SERUM BICARBONATE MEASUREMENTS AND RISK OF CHRONIC KIDNEY DISEASE PROGRESSION AND MORTALITY: INSIGHTS FROM THE CKD-REIN COHORT. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
259	P0789 SERUM URIC ACID IS ASSOCIATED WITH CHRONIC KIDNEY DISEASE PROGRESSION AND MORTALITY: INSIGHTS FROM THE CKD-REIN COHORT. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
260	The Authors Reply. Kidney International Reports, 2020, 5, 2403-2404.	0.8	0
261	Hyponatremia under MAP kinase inhibitors: a complex relationship between aquaporins and ERK activation. Kidney International, 2021, 99, 488.	5.2	0
262	MO484 ADVERSE OUTCOMES ASSOCIATED WITH ORAL ANTITHROMBOTIC USE IN PATIENTS WITH MODERATE-TO-ADVANCED CHRONIC KIDNEY DISEASE*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
263	MO496 PRESCRIPTION OF DIRECT ORAL ANTICOAGULANTS TO PATIENTS WITH MODERATE TO ADVANCED CKD : TOO LITTLE OR JUST RIGHT?. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
264	Heterogeneous neutralizing antibodies production after Sars-Cov2 vaccination in hemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 2616-2617.	2.9	0
265	Glomerulonephritis with non-Randall-type, non-cryoglobulinemic monoclonal immunoglobulin G deposits [PGNMID and ITC]. CKJ: Clinical Kidney Journal, 0, , .	2.9	0
266	Title is missing!. , 2020, 15, e0229145.		0
267	Title is missing!. , 2020, 15, e0229145.		0
268	Title is missing!. , 2020, 15, e0229145.		0
269	Title is missing!. , 2020, 15, e0229145.		0
270	MO503: Cognitive Performance in Patients With Chronic Kidney Disease: Results From the CKD-Rein Cohort Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0

#	ARTICLE	IF	CITATIONS
271	MO499: Incidence of Cause-Specific Cardiovascular Events in Men and Women With CKD. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0